ClinicalTrials.gg
CompletedNCT07430475Updated Feb 24, 2026

Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study

An observational study in Fever of Unknown Origin, Inflammation of Unknown Origin and Fever, sponsored by University of Adelaide. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Adelaide · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
266
Ages
18 Years and older
Sex
All
01

Study summary

Retrospective cohort study of inpatients at a South Australian tertiary hospital who underwent 18F FDG-PET/CT for investigation of undifferentiated fever or inflammatory syndrome. The aim is to investigate the utility of FDG-PET/CT in the investigation of suspected infection in hospitalised adults. To establish the rate at which FDG-PET/CT contributes to a diagnosis, and how this impacts clinical management and outcomes. From this, to develop further understanding of for which patients this imaging modality contributes meaningfully to outcomes.

Read the detailed description

A retrospective cohort study of consecutive adult inpatients undergoing 18F-FDG PET/CT for suspected infection or inflammation, excluding infective endocarditis and malignancy-directed scans. Pre-PET variables include inflammatory markers, microbiological results, prior imaging findings and infectious diseases (ID) consultation. PET/CT utility will be adjudicated as diagnostic and/or associated with a change in management using a structured consensus process. Associations between pre-PET factors and clinical utility will be explored using descriptive and logistic analyses.

02

Conditions studied

  • Fever of Unknown Origin
  • Inflammation of Unknown Origin
  • Fever
  • Inflammation

Keywords

  • FDG-PET/CT
  • PET
  • fever of unknown origin
03

In context

Fever of Unknown Origin

21 studies on the registry are indexed under Fever of Unknown Origin; 2 are open to participants now.

This study's enrollment of 266 is above the median of 100 across 11 observational studies indexed under Fever of Unknown Origin.

Browse Fever of Unknown Origin studies →

Lead sponsor

University of Adelaide is the lead sponsor of 42 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adults referred for FDG-PET/CT for evaluation of undifferentiated fever, inflammation or infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatient at the Royal Adelaide Hospital
  • FDG-PET/CT between 1st January 2022 - 31st December 2023
  • Imaging request query included: infect* AND/OR Fever of Unknown Origin OR FUO AND/OR Pyrexia of Unknown Origin OR PUO AND/OR inflammat*

Exclusion criteria

Exclusion Criteria:

  • - Outpatient PET/CT
  • Comparison imaging for established diagnosed infection
  • PET/CT intended for evaluation of
  • Evaluation of presumed or confirmed infective endocarditis
  • Age less than 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
266 participants (actual)
Patient registry
No

Groups and cohorts

  • Infectious diseases consultation

    Diagnostic Test: 18F-FDG PET/CT

  • No infectious diseases consultation

    Diagnostic Test: 18F-FDG PET/CT

  • Significant pre-PET imaging finding

    Diagnostic Test: 18F-FDG PET/CT

  • No significant pre-PET imaging finding

    Diagnostic Test: 18F-FDG PET/CT

  • High blood WCC prior to PET

    Diagnostic Test: 18F-FDG PET/CT

  • Low WCC prior to PET

    Diagnostic Test: 18F-FDG PET/CT

  • High CRP prior to PET

    Diagnostic Test: 18F-FDG PET/CT

  • Low CRP prior to PET

    Diagnostic Test: 18F-FDG PET/CT

Interventions

  • Diagnostic test18F-FDG PET/CT

    Nuclear medicine imaging as a diagnostic tool with implication for change in clinical management

06

What researchers measure

Primary outcomes

  1. Diagnostic yield

    • Did PET contribute to diagnostic yield?: * 1 = Yes: PET led to a finding either definitive e.g. confirmed by gold standard (microbiology, histopathology, intraoperative findings etc) or contributory, which guided diagnosis or management even without gold standard confirmation. Examples of contributory: PET showing vascular graft uptake, not explanted due to risk but presumptively treated Vertebral discitis suggested by PET, biopsied without culture, but presumptively treated and clinically improved PET negative - antibiotics ceased, patient remained well * 0 = No: PET provided no new information, was misleading (i.e. PET result contradicted by later results), or no action was taken based on PET

    Time frame: 30 days

Secondary outcomes

  1. Clinical change in management

    • Clinical change in management: was clinical care altered compared to the documented plan prior to PET? 0 = no, 1 = yes * Yes: antimicrobial therapy, procedures/interventions (PET-guided site biopsy, or surgery/drainage), diagnostics e.g. further focussed imaging, or disposition e.g. palliative care transition * No: there was no change to the management plan, or the plan was already determined by other data Examples: * PET confirmed a suspected diagnosis but the treatment plan was unchanged * PET provided supporting evidence but no explicit management adjustment was documented * PET was negative and no further management steps were taken because there was a pre-existing plan

    Time frame: 30 days

  2. Change in antimicrobial management

    •Change in antimicrobial duration/spectrum/therapeutic procedure: this change occurred as a result of PET

    Time frame: 30 days

  3. Final diagnosis

    • Final diagnosis: infection = 1, non-infectious = 2, malignancy = 3, unresolved = 4

    Time frame: 30 days

07

Study locations

1 site
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2024, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Jan 4, 2022
Primary completionActual
Jan 29, 2024
CompletionActual
Jan 29, 2024
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07430475
Lead sponsor
University of Adelaide
Collaborators
Central Adelaide Local Health Network Incorporated
Responsible party
James Kimber (Dr, University of Adelaide) — Principal investigator
First posted
Feb 24, 2026
Start date
Jan 4, 2022
Primary completion
Jan 29, 2024
Completion
Jan 29, 2024
Last update
Feb 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion